<DOC>
	<DOCNO>NCT00946881</DOCNO>
	<brief_summary>The aim study determine optimal treatment condition ( WST11 dose light energy dose ) achieve ablation one lobe prostate evaluate safety quality life WST11 medicate Vascular-Targeted Photodynamic therapy ( VTP ) men localize prostate cancer .</brief_summary>
	<brief_title>Safety Tolerability Study Using WST11 In Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>This study design multicenter , phase I/II , prospective , open-labeled , single intravenous ( IV ) dose , clinical trial patient localized prostate cancer . The study population men offer curative therapy ( radical prostatectomy ; cryotherapy ; brachytherapy ; EBRT ) , refuse . Patients must already previous biopsy show histologically proven carcinoma prostate . The identification location tumor do use dynamic contrast MRI biopsy . Only unilateral treatment WST11-medicated VTP perform study . Treatment consist single , 10 minute , IV administration WST11 dose 2mg/kg , 4 mg/kg 6 mg/kg , follow either light activation deliver transperineal interstitial optical fiber 20 minute use 753 nm laser light escalate fix energy dos 200 J/cm 300 J/cm escalate power energy 167 mW/cm 250 mW/cm respectively . A brachytherapy-like template use placement transparent implant catheter position prostate transrectal ultrasound image guidance . The illumination fiber ( ) insert implant catheter . If safety profile give WST11 light dose acceptable , additional patient ( 3 ) may treat multiple fiber WST11 treatment dose . For case Month 6 biopsy positive , patient offer opportunity retreat WST11</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>At least 18 year age Diagnosed localize , prostate cancer offer curative therapy ( radical prostatectomy ; cryotherapy ; brachytherapy ; EBRT ) , refuse Localized prostate cancer stage T1C T2A base biopsy perform least 6 week prior enrollment Gleason score ≤ 3+3 ≤50 % sampled core positive , positive core tumour length ≤5 mm PSA &lt; 10 ng/mL No prior treatment prostate cancer Signed Informed Consent Form Any condition history illness surgery , opinion investigator and/or Sponsor , might confound result study pose additional risk patient . All patient whose current preoperative cardiac evaluation show fitness procedure require general anesthesia ; Patients prior history viral alcoholic hepatitis , patient felt risk hepatotoxicity include concomitant use potentially hepatotoxic medication dietary supplement ; Patients history inflammatory bowel disease factor may increase risk fistula formation ; Patients receive hormonal manipulation ( exclude 5alpha reductase inhibitor ) androgen supplement within previous 6 month ; Patients previously treat radiation therapy ( external therapy brachytherapy ) chemotherapy therapy prostate cancer ; Patients receive receive chemotherapy prostate carcinoma significant cancer ; Patients undergo previous TURP ( transurethral resection prostate ) ; Patients history urethral stricture disease Patients history acute urinary retention Patients currently ( within 10 day treatment procedure ) receive medication potential photosensitizing effect ( e.g . tetracycline , sulfonamide , phenothiazine , sulfonylurea hypoglycemic agent , thiazide diuretic griseofulvin ) Patients currently receive anticoagulant drug ( within 10 day treatment procedure ) ( e.g . : coumadin , warfarin ) Patient stop long term treatment acetylsalicylic acid ( aspirin ) anti platelets agent within 10 day prior treatment procedure ; Patient suspect Disseminated Intravascular Coagulation ( DIC ) define presence three five follow criterion : platelet decrease , increase PT , increase aPTT , fibrinogen decrease , DDimer increase ; normal laboratory range ; Patient history vasculitis collagen vascular disease ; History non compliance medical therapy medical recommendation unwillingness inability complete patient selfadministered questionnaire ; Participation clinical study receipt investigational treatment within past 3 month ; A history porphyria ; A history sun hypersensitivity photosensitive dermatitis ; Renal disorder ( blood creatinine &gt; 1.5 x ULN ) know post mictional residue &gt; 150cc Hepatic disorder ( transaminase &gt; ULN , bilirubin &gt; ULN , GGT &gt; ULN ) . In case slight abnormality , another exam could perform . If result within normal range , patient include ; Hematological disorder ( white cell &lt; 2500/mm3 , neutrophil &lt; 1500/mm3 , platelet , &lt; 140.000/mm3 , Hb ≤ 10 g/dL ) ; Patients contraindication MRI ( pace maker , metal prosthesis , etc . ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Prostatic disease</keyword>
	<keyword>genital neoplasm , male</keyword>
	<keyword>Urogenital neoplasm</keyword>
	<keyword>Genital disease</keyword>
	<keyword>male</keyword>
	<keyword>Male urogenital disease</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasm site</keyword>
	<keyword>prostatic neoplasm</keyword>
	<keyword>Carcinoma</keyword>
</DOC>